Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5616717 | 0.98 | TDP1 (0.55) | TDP1HCAR2ESR1ESR2NPC1 | |
| SCHEMBL11299427 | 0.81 | CHRNB2 (0.55) | TDP1HCAR2ESR1ESR2NPC1 | |
| SCHEMBL2773501 | 0.81 | ALDH1A1 (0.57) | TDP1HCAR2L3MBTL1ALDH1A1HPGD | |
| SCHEMBL14690907 | 0.80 | TDP1 (0.54) | TDP1HCAR2ESR1ESR2NPC1 | |
| SCHEMBL448069 | 0.79 | ALDH1A1 (0.55) | TDP1HCAR2L3MBTL1ALDH1A1HPGD | |
| SCHEMBL22832718 | 0.79 | TDP1 (0.81) | TDP1HCAR2ESR1ESR2NPC1 | |
| SCHEMBL3486307 | 0.79 | HCAR2 (0.58) | TDP1HCAR2ESR1ESR2NPC1 | |
| SCHEMBL872143 | 0.78 | HCAR2 (0.61) | TDP1HCAR2ESR1ESR2NPC1 | |
| SCHEMBL983427 | 0.78 | HCAR2 (0.61) | TDP1HCAR2ESR1ESR2NPC1 | |
| SCHEMBL14694691 | 0.78 | HCAR2 (0.61) | TDP1HCAR2ESR1ESR2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9949961-B2 | Agent for the prophylaxis and/or treatment of neoplastic diseases | ROZIEV RAHIMDZHAN (RU) | 2018-04-24 | — | — | US | disclosed |
| US-20160038472-A1 | AGENT FOR THE PROPHYLAXIS AND/OR TREATMENT OF NEOPLASTIC DISEASES | TIATSEN LTD (RU) | 2016-02-11 | — | — | US | disclosed |
| EP-2974726-A1 | AGENT FOR THE PROPHYLAXIS AND/OR TREATMENT OF NEOPLASTIC DISEASES | Tiacen Ltd (RU) | 2016-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160038472-A1 | AGENT FOR THE PROPHYLAXIS AND/OR TREATMENT OF NEOPLASTIC DISEASES | VHL, BRCA1, TSG101 | TDP1 2331/4885HCAR2 786/4885ESR1 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.